Published on : Apr 17, 2017
Albany, New York, April 17, 2017: Over the past few years, multiple clinical trials have reported results that will influence the treatment of patients with acute coronary syndrome (ACS) for many years to come. However, large-scale clinical trials take years to complete, during which time the underlying landscape may shift. Market Research Hub (MRH) has recently announced the inclusion of a new study titled “Acute Coronary Syndrome Global Clinical Trials Review, H1, 2017” to its wide research offerings, which provides a detailed snapshot of the global clinical trials landscape. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc. across the globe.
Acute coronary syndrome is one of the serious medical conditions, which covers a range of disorders, from a heart attack (myocardial infarction) to unstable angina. Based on evidence of heart muscle damage, the acute coronary syndrome is divided into two main types:
- ST-elevation myocardial infarction (STEMI)
- Non-ST-elevation myocardial infarction (NSTEMI).
Acute coronary syndrome often causes severe chest pain or discomfort to the patients. It is a medical emergency that requires quick diagnosis and care with the better treatment. Treatment goals include improving blood flow, treating difficulties and avoiding future problems.
This report delves into the various facets of the rising prominence of pipeline drugs, therapeutics, and other remedial measures for Acute coronary syndrome global clinical trials. Additionally, the report offers coverage of disease clinical trials by regions, phase, country (G7 & E7), trial status, end points status and sponsor type. By region, the report analyzes top five countries contributing to the clinical trial of ACT, such as Europe, Asia-Pacific, North America, Central and South America, and Middle East & Africa. Currently, extensive pipeline drugs with properties, such as high patient compliance and improved safety, are also supporting the growth of global acute coronary syndrome market.
For the buyers, this report provides top-line data relating to the ongoing and completed clinical trials on Acute Coronary Syndrome. For the brief description with key insights, the report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. With the key details about the disease and its global market overview, report enhances the decision-making capabilities for the readers and helps to create effective counter strategies to gain competitive advantage.
Furthermore, the report also reviews top companies involved and enlists all trials (Trial title, Phase and Status) relating to the company. Currently, top companies participating in acute coronary syndrome therapeutics clinical trials are as follows:
- Daiichi Sankyo Company Ltd
- AstraZeneca Plc
- The Medicines Company
- Eli Lilly and Company
- Merck & Co Inc
- Pfizer Inc
- Bristol-Myers Squibb Company
- Bayer AG
- Astellas Pharma Inc
Click here to get more info with TOC in a PDF Format: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1054400
At last, the report concludes with details on prominent drugs and clinical trial profile snapshots.
About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
For Enquiries, Call :
+1-866-997-4948US Toll Free
Email : firstname.lastname@example.org